Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Eli Lilly, Etsy, Lear, Netskope, Nokia, Northrop Grumman, Rapid7, Rivian Automotive, Ulta Beauty, and More
Wall Street analysts issued research calls on several companies. Eli Lilly (LLY) was upgraded to Buy with a $1,400 target, Etsy (ETSY) to Outperform with a $525 target, and New York Times (NYT) to Buy with an $82 target. Downgrades included Aptiv (APTV) to Neutral with a $56 target, Lear (LEA) to Neutral with a $150 target, and Magna (MGA) to Neutral with a $72 target. New initiations included Autodesk (ADSK) with a Neutral rating and $215 target, Rivian (RIVN) with a Neutral rating and $18 targ
How this was made
The 30-second read
Why it matters
Collective rating changes provide fresh guidance for traders; individual impacts vary by company.
Market read
Analyst rating updates can trigger short-term price moves and inform portfolio rebalancing.
What to watch
Potential macro headwinds from upcoming Fed rate decision could dampen reactions.
Background
Daily analyst research roundup highlighting upgrades, downgrades, and initiations across multiple US-listed firms.
Ticker impact
Upgraded to Buy from Hold with price target raised to $1,400.
Modest price rise expected on upgrade.
Upgrade signals improved outlook; target increase adds upside.
Upgraded to Outperform from Perform with target raised to $525.
Small to moderate gain.
Higher target reflects stronger earnings expectations.
Raised to Buy from Neutral with target increased to $82.
Potential modest rally.
Analyst confidence improves market perception.
Upgraded to Outperform from Sector Perform with target $262.
Limited upside.
Target raise signals better outlook.
Upgraded to Equal Weight from Underweight with target $525.
Small upside possible.
Analyst view improves relative positioning.
Downgraded to Neutral from Overweight with target $56.
Potential modest decline.
Reduced rating signals weaker outlook.
Downgraded to Neutral from Overweight with target $150.
Possible slight drop.
Analyst reduces confidence.
Downgraded to Neutral from Overweight with target $72.
Modest downside.
Target cut reflects weaker expectations.
Market effects
Analyst rating changes may affect healthcare, tech, consumer discretionary sectors.
US equity markets may see modest shifts across sectors.
Limited; primarily US-listed companies.
Counterpoint
Some investors may view upgrades as already priced in, limiting upside.
Key entities
- Research FirmBerenberg
Upgraded Eli Lilly to Buy.
- Research FirmOppenheimer
Upgraded Etsy to Outperform.
- Research FirmJPMorgan
Downgraded several names.
